Intelligent Bio Solutions closes $10M private placement; funds FDA submission and expansion

INTELLIGENT BIO SOLUTIONS INC.

Gross proceeds of ~$10M from sale of 2,298,850 units at $4.35/unit (common/pre-funded warrant + two Series K warrants).
At closing, 105,000 shares and 2,193,850 pre-funded warrants issued; post-closing shares outstanding ~1.2M (excluding warrants).
Series K warrants exercisable at $4.10/share for 5 years after registration statement declared effective by SEC.
CEO: proceeds to fund FDA 510(k) submission for fingerprint drug screening system and international market expansion.
Closing on Jan 2, 2026; resale registration statement to be filed by Jan 10, effective by Feb 14, 2026.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

INTELLIGENT BIO SOLUTIONS INC. entered into Securities Purchase Agreement with two healthcare focused institutional investors valued at approximately $10.0 million (effective 2025-12-31).

Action: entry
Agreement: equity purchase
Counterparty: two healthcare focused institutional investors
Value: approximately $10.0 million
Effective: 2025-12-31

Exact text from the filing

On December 31, 2025, Intelligent Bio Solutions Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with two healthcare focused institutional investors for the sale by the Company of (i) 2,298,850 shares (the “Shares”) of the Company’s common stock (or Series L Pre-funded warrants in lieu thereof (the “Pre-Funded Warrants”)), par value $0.01 per share (the “Common Stock”), (ii) Series K-1 warrants to purchase up to an aggregate of 2,298,850 shares of Common Stock (the “Series K-1 Warrants”), and (iii) Series K-2 warrants to purchase up to an aggregate of 2,298,850 shares of Common Stock (the “Series K-2 Warrants” and, collectively with the Series K-1 Warrants and Pre-Funded Warrants, the “Warrants”), in a private placement offering (the “Offering”).

View on SEC.gov

290 material agreements filed in the last 30 days. Browse all material agreements →

INTELLIGENT BIO SOLUTIONS INC. filing history →

Source: SEC EDGAR

accession 0001493152-26-000176

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.